Horizon Therapeutics (HZNP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 389,796 | 199,239 | -93,601 | -13,591 | 573,020 |
| Depreciation Amortization | 292,091 | 221,931 | 150,213 | 71,310 | 259,759 |
| Income taxes - deferred | -33,453 | -8,041 | -4,561 | -2,082 | -565,537 |
| Accounts receivable | -251,173 | -297,392 | -135,125 | -16,869 | 56,166 |
| Accounts payable and accrued liabilities | 16,015 | 17,709 | 83,555 | 28,551 | -8,723 |
| Other Working Capital | -345,675 | -461,549 | -163,953 | -174,461 | -2,497 |
| Other Operating Activity | 488,087 | 473,974 | 200,480 | 44,549 | 114,144 |
| Operating Cash Flow | $555,688 | $145,871 | $37,008 | $-62,593 | $426,332 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -164,452 | -133,399 | -119,970 | -119,004 | -11,857 |
| Net Acquisitions | -262,305 | -262,305 | -262,305 | -105,200 | N/A |
| Purchase Of Investment | -14,108 | -8,937 | N/A | N/A | N/A |
| Sale Of Investment | 794 | N/A | N/A | N/A | N/A |
| Purchase Sale Intangibles | -30,000 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -24,000 | 6,000 | 6,000 | 6,000 | -6,000 |
| Investing Cash Flow | $-464,071 | $-398,641 | $-376,275 | $-218,204 | $-17,857 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 0 | N/A | 1,525,461 |
| Debt Repayment | -1,739 | -1,739 | 0 | N/A | -2,150,627 |
| Common Stock Issued | 972,823 | 961,973 | 33,866 | 7,050 | 362,992 |
| Other Financing Activity | -66,505 | -59,752 | -53,009 | -46,664 | -28,272 |
| Financing Cash Flow | $904,579 | $900,482 | $-19,143 | $-39,614 | $-290,446 |
| Exchange Rate Effect | 7,244 | 1,225 | 58 | -1,366 | -107 |
| Beginning Cash Position | 1,080,039 | 1,080,039 | 1,080,039 | 1,080,039 | 962,117 |
| End Cash Position | 2,083,479 | 1,728,976 | 721,687 | 758,262 | 1,080,039 |
| Net Cash Flow | $1,003,440 | $648,937 | $-358,352 | $-321,777 | $117,922 |
| Free Cash Flow | |||||
| Operating Cash Flow | 555,688 | 145,871 | 37,008 | -62,593 | 426,332 |
| Capital Expenditure | -169,852 | -133,399 | -119,970 | -119,004 | -17,857 |
| Free Cash Flow | 385,836 | 12,472 | -82,962 | -181,597 | 408,475 |